CD274 and neoplasm: Biomarkers approved by regulatory authorities to predict the likelihood of response to the anti‐PD‐1 monoclonal antibody pembrolizumab include PD‐L1 expression for several tumor types and TMB or MSI regardless of specific cancer.3